News
Novo Nordisk ousts CEO
Digest more
As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...
"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback